drugset
drugset / Trial / NCT01266902

A Trial With TMC278-TIDP6-C222 for Continued TMC278 Access in Patients Infected With Human Immunodeficiency Virus-1

NCT01266902 ↗

Phase 3 Completed 482 enrolled Janssen R&D Ireland
NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to provide continued access to TMC278 in HIV-1 infected patients who were randomized and treated with TMC278 in the Phase IIb or Phase III trials.

Timeline

Start
2011-02
Primary completion
2020-02
Completion
2020-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Rilpivirine Small molecule 25 mg Oral

Indications

HIV infectious disease